Oscar Health, Inc. (OSCR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Oscar Health, Inc. operates as a single reportable segment, providing health insurance to individuals and families primarily through the Affordable Care Act (ACA) marketplaces. As of June 30, 2025, the Company reported approximately 2.0 million effectuated members, a 28% increase year-over-year. In May 2025, the Company acquired three businesses operating in the individual market: INSXCloud, Inc., IHC Specialty Benefits, Inc., and Healthinsurance.org, LLC.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $2,863,945 | $2,219,341 | $5,910,208 | $4,361,646 |
| Premium Revenue | $2,803,444 | $2,164,116 | $5,799,265 | $4,257,798 |
| Net Income (Loss) | $(228,491) | $56,312 | $47,015 | $233,794 |
| Net Income (Loss) Attributable to Oscar | $(228,361) | $56,207 | $46,910 | $233,575 |
| Earnings (Loss) Per Share (Diluted) | $(0.89) | $0.20 | $0.17 | $0.82 |
| Medical Loss Ratio (MLR) | 91.1% | 79.0% | 83.0% | 76.7% |
| SG&A Expense Ratio | 18.7% | 19.6% | 17.2% | 19.0% |
| Cash and Cash Equivalents | $2,598,942 | N/A | N/A | N/A |
| Long-Term Debt (Carrying Value) | $299,944 | N/A | N/A | N/A |
Material Changes vs. Prior Period
- Profitability Reversal: The Company reported a net loss of $228.5 million for Q2 2025, compared to a net income of $56.3 million in Q2 2024. This reversal was primarily driven by a significant increase in the net risk adjustment transfer accrual.
- Revenue Growth: Total revenue increased 29% year-over-year in Q2 2025, driven by a 28% increase in membership (adding 0.4 million members). However, this growth was partially offset by higher risk adjustment payables.
- Medical Loss Ratio Deterioration: The MLR increased to 91.1% in Q2 2025 from 79.0% in Q2 2024. Management attributes this to increased average market morbidity and the resulting increase in net risk adjustment transfer accruals.
- SG&A Efficiency: While SG&A expenses increased 23% year-over-year due to higher membership, the SG&A expense ratio improved to 18.7% from 19.6%, driven by lower exchange fee rates and fixed cost leverage.
- Accounting Adjustment: The Company recorded a $14.9 million adjustment in SG&A expenses in Q2 2025 related to an understatement of expenses in the 2023-2024 periods. Management determined this was not material to prior periods.
Guidance, Outlook, Risks, and Unusual Items
- Risk Adjustment Volatility: In July 2025, the Company received third-party reports indicating a meaningful market-wide increase in morbidity for 2025. Consequently, the Company significantly increased its estimate of the net risk adjustment payable for the 2025 policy year. This estimate is subject to high variability and final CMS reporting, which may occur up to 12 months in arrears.
- Regulatory Headwinds: The Company faces potential headwinds from the expiration of enhanced Advanced Premium Tax Credits (APTCs) at the end of 2025 unless renewed by Congress. Additionally, new CMS "Program Integrity Rules" and the "One Big Beautiful Bill Act" (OBBBA) are expected to reduce marketplace participation and complicate enrollment verification.
- Debt Convertibility: The Company's $305 million Convertible Senior Notes due 2031 became convertible at the option of the holder during Q3 2025 after the stock price condition was met in Q2 2025. As of the filing date, no conversion has occurred.
- Liquidity: The Company maintains strong liquidity with $2.6 billion in cash and cash equivalents. Health insurance subsidiaries held approximately $579 million in excess capital above statutory requirements as of June 30, 2025.
- Legal Proceedings: A securities class action lawsuit regarding the IPO was dismissed with prejudice in April 2025. The Company remains subject to various regulatory reviews and potential fines.
Key Facts for Investor Verification
- Risk Adjustment Estimates: Verify the sensitivity of the Q2 2025 loss to the specific third-party morbidity data received in July 2025 and the potential for further adjustments in future quarters.
- Membership Quality: Assess the impact of the 28% membership growth on the Medical Loss Ratio, specifically regarding the mix of new enrollees from Medicaid redeterminations and Special Enrollment Periods.
- Regulatory Impact: Monitor the implementation of the CMS Program Integrity Rules and the OBBBA, and their potential to reduce the overall size of the ACA marketplace and Oscar's member base.
- Debt Conversion Risk: Track the potential conversion of the $305 million 2031 Notes, which could result in significant dilution if holders elect to convert to equity.
- Capital Requirements: Confirm that the health insurance subsidiaries maintain sufficient excess capital to meet statutory requirements, especially given the volatility in risk adjustment payables.